For the paper, published in the New England Journal of Medicine, experts from UCL, Royal Free Hospital and biotechnology company Freeline Therapeutics trialled and continue to evaluate a new type of adeno-associated virus (AAV) gene therapy candidate, called FLT180a, to treat severe and moderately severe cases of the condition.
The Phase I/II trial was sponsored by UCL and funded by Freeline Therapeutics.
Read the full story here.
We make UCL’s research physical and life sciences ideas happen.